Latest Breaking News On - Neximmune inc - Page 18 : comparemela.com

Grant Verstandig Acquires 39,995 Shares of NexImmune, Inc (NASDAQ:NEXI) Stock

NexImmune, Inc. (NASDAQ:NEXI – Get Rating) Director Grant Verstandig purchased 39,995 shares of NexImmune stock in a transaction dated Thursday, March 24th. The stock was bought at an average price of $3.35 per share, for a total transaction of $133,983.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which […]

New yorkUnited statesRaymond jamesYork state common retirement fundSecurities exchange commissionZacks investment researchDe shaw coCantor fitzgeraldWells fargo companyNeximmune incCitigroup incRoyal bankGet ratingDirector grant verstandigExchange commissionGrant verstandig

NexImmune, Inc (NASDAQ:NEXI) to Post FY2022 Earnings of ($1 91) Per Share, Cantor Fitzgerald Forecasts

NexImmune, Inc. (NASDAQ:NEXI – Get Rating) – Research analysts at Cantor Fitzgerald upped their FY2022 earnings per share estimates for NexImmune in a note issued to investors on Tuesday, March 15th. Cantor Fitzgerald analyst A. Young now forecasts that the company will post earnings of ($1.91) per share for the year, up from their previous […]

New yorkUnited statesRaymond jamesCantor fitzgeraldNeximmune incZacks investment researchBlackrock incFirst manhattan coVanguard group incGet ratingInvestment researchArtificial immune modulationNasdaq nexiEarnings estimates

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Davidl morganKatie griffKristi jonesExchange commissionNeximmune incCorporate affairsArtificial immune modulationPrivate securities litigation reform actAnnual report

NexImmune Announces Melanoma Research Collaboration with NYU Langone s Perlmutter Cancer Center

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter .

Jeffrey weberJeffreys weberKristi jonesLangone healthNational cancer instituteIsaac perlmutter cancer centerCancer centerExchange commissionNeximmune incCorporate affairsComprehensive cancer centerDeputy directorChief executive officerArtificial immune modulationScientific advisory boardPrivate securities litigation reform act

NexImmune Announces Melanoma Research Collaboration with NYU Langone s Perlmutter Cancer Center

GAITHERSBURG, MD, March 14, 2022 NexImmune, Inc. , a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by. | March 14, 2022

Jeffrey weberJeffreys weberKristi jonesLangone healthNational cancer instituteIsaac perlmutter cancer centerCancer centerExchange commissionNeximmune incCorporate affairsComprehensive cancer centerDeputy directorChief executive officerArtificial immune modulationScientific advisory boardPrivate securities litigation reform act